Weleda AG, the global market leader in certified natural cosmetics and anthroposophic medicines, announced strong financial results for the 2024 financial year. The company reported an 8.3% increase in turnover, reaching a record high of EUR 456.2 million. Furthermore, Weleda’s operating profit more than doubled, rising from EUR 13.4 million to EUR 28.3 million.
Both business units – Natural Cosmetics and Pharmaceuticals – contributed to the company’s successful performance with strong growth worldwide. Weleda’s strategic focus on internationalisation, digitalisation, innovation, and premiumisation has proven to be effective in driving growth. CEO Tina Müller commented, “2024 was a year of renewal for Weleda – and a very strong year for us economically. Our strategy of growth with responsibility is working.”
Weleda’s positive performance was supported by its expansion into international markets, with double-digit sales growth in major markets such as Asia and the USA, as well as in Eastern Europe, Southern Europe, and the Benelux countries. The company also saw a strong recovery in its core D-A-CH region after several challenging years. In Germany, Weleda’s largest single market, sales increased by 6.2%, and in Switzerland, turnover rose by 7.4%.
In 2024, Weleda demonstrated strong innovative capacity with the launch of new products such as the rejuvenating Blue Gentian & Edelweiss facial care and the extended Rosemary hair care line. In the pharmaceuticals segment, the company’s strategic focus on core product categories – eye health, stress & sleep, and digestion – resulted in a 32% increase in sales for eye preparations.
To further strengthen its competitiveness and resilience, Weleda implemented a new organisational structure at the beginning of 2024. This included dedicated business units for Natural Cosmetics and Pharmaceuticals and stronger central functions. CEO Tina Müller stated, “The new organisational structure has made us faster, more efficient, and more effective, which benefits our customers worldwide.”
Sustainability remains a core value for Weleda, and the company actively supports biodiversity, healthy soils, and the circular economy. In 2024, Weleda sharpened its sustainability strategy and set ambitious new targets, including achieving net zero for Scope 1 and 2 emissions by 2040 and reducing Scope 3 emissions by 80% by that time.
Weleda’s future will be driven by innovation, with plans to launch new product ranges in Natural Cosmetics, such as the multi-generation skincare line minLen, and expand into the premium segment. In Pharmaceuticals, an interdisciplinary team called Futurum has been formed to further develop anthroposophic medicines and introduce new application formats to benefit patients.
To appeal to younger target groups, Weleda has modernised its brand image, including its logo, to make it more contemporary and premium. The company will also be rolling out a new brand identity across markets throughout 2025.
“We have set the course for long-term success in every respect. We have again started the new financial year with strong momentum and will continue on our growth path with many innovations,” said CEO Tina Müller.
For more information about Weleda, please visit www.weleda.com.
Media Contact:
Yvonne Samaritani
Group Corporate Communications Officer
Weleda AG/Dychweg 14/CH-4144-Arlesheim
presse@weleda.de
Distributed by https://pressat.co.uk/
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.